Bizarre Patents
Process For Propelling Foodstuffs or the Like into a Crowd
A method of launching foodstuffs into a crowd for promotional and entertainment purposes.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7301023 | Chiral salt resolution A method for resolving enantiomers of a compound containing the structure of the forula: wherein R4 or R5 may contan one or more asymmetric centers, by mixing a racemic mixture of enantiomers of a... | 11/27/2007 |
| 7122534 | Aryl fused azapolycyclic compounds The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein, intermediates in the synthesis of ... | 10/17/2006 |
| 7122565 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors The invention provides 1,3,4-thiadiazoles and 1,3,4-oxadiazoles having the following Formula I: in which, Y is S or O, R1 is alkyl, alkenyl, alkynyl, cyclo... | 10/17/2006 |
| 7109228 | Pyrazole derivatives This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their prepa... | 09/19/2006 |
| 7101869 | 2,4-diaminopyrimidine compounds useful as immunosuppressants Novel compounds according to the formula and pharmaceutically acceptable salts, solvates, or hydrates thereof; wherein each occurrence of A is independently selected from CH or... | 09/05/2006 |
| 7101878 | Non-peptide GNRH agents, methods and intermediates for their preparation Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorde... | 09/05/2006 |
| 7067493 | Single dose azithromycin The present invention relates to a method of treating infections in humans by administering a single dose of azithromycin. ... | 06/27/2006 |
| 7053192 | Crystal forms of azithromycin The invention relates to novel crystal forms of azithromycin, an antibiotic useful in the treatment of infections. ... | 05/30/2006 |
| 7041667 | CCR5 modulators Compounds of Formula 1 [Region α]—[Region β]—[Region γ]—[Region δ] (1) which are useful as modulators of chemokine activity. The invention also provides pharmaceutical formulations and m... | 05/09/2006 |
| 7022684 | Treatment of rumen acidosis with α-amylase inhibitors The invention described herein relates to: the use of an effective inhibitor of a bacterial α-amylase and/or α-glucosidase in the manufacture of a composition for the treatment of rumen acidosis; a method of treatment of rumen acidosis which comprises administrati... | 04/04/2006 |
| 7019033 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula where R1, R2, R3, R4, R5, and R6 are hydrog... | 03/28/2006 |
| 7019016 | NMDA NR2B antagonists for treatment The invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of NR2B subunit selective NMDA antagonists. The disorders that can be treating by the invention include heari... | 03/28/2006 |
| 6992087 | Substituted aryl 1,4-pyrazine derivatives Substituted aryl 1,4-pyrazine derivatives of formula I as defined herein and their use in treating anxiety disorders, depression and stress related disorders are disclosed. ... | 01/31/2006 |
| 6979741 | Acetyl-CoA carboxylase inhibitors Acetyl Coenzyme A Carboxylase inhibitors, pharmaceutical compositions containing such compounds and the use of such compounds to treat for example, Metabolic Syndrome including atherosclerosis, diabetes and obesity. ... | 12/27/2005 |
| 6977302 | Triazole derivatives useful in therapy The invention provides compounds of formula I, R1—OP(O)(OH)2 I wherein R1 represents the non-hydroxy portion of a triazole antifungal compound of the type comprising a tertiary hydroxy group; or a pharmaceu... | 12/20/2005 |
| 6974803 | Pharmaceutical combination The present invention relates to a combination comprising (a) an adenosine A2a receptor agonist as defined herein and (b) an adrenergic β2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of ... | 12/13/2005 |
| 6974828 | Propanoic acid derivatives as intergrin receptor antagonists Novel propanoic acid derivatives are integrin receptor antagonists or inhibitors, in particular of the avb3 integrin receptor. The compounds of the invention are for instance useful for the treatment of solid tumors by inhibition of angiogenic growth of tumor vessel... | 12/13/2005 |
| 6972287 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits The present invention provides a method of treating Alzheimer's disease using a compound of Formula (I). Also provided is a method of inhibiting the aggregation of amyloid proteins using a compound of the Formula (I) and a method of imaging amyloid deposits, as well... | 12/06/2005 |
| 6972298 | Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor The present invention provides a method of treating or preventing neutrophil chemotaxis. Specifically, the present invention provides a method of treating or preventing neutrophil migration by administering to a patient a MEK inhibitor. ... | 12/06/2005 |
| 6967204 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors This invention is directed to a method of treating insulin resistance syndrome (IRS), hypertension and/or type 2 diabetes in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor or a pharmaceutical composition thereof. This invention is also direct... | 11/22/2005 |
| 6964957 | Fused pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity Pyrazole compounds represented by the formula: are described. The pyrazole compounds and pharmaceutical compositions containing them may be used in inhibiting ERAB or HADH2 activity and in treating ERAB, HADH2 or amylo... | 11/15/2005 |
| 6964965 | Substituted pyrazine derivatives The present invention provides substituted pyrazine derivatives of Formula I, that are CRF1 receptor antagonists, including human CRF1 receptors. This invention also relates to use of compounds of... | 11/15/2005 |
| 6962912 | Substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them The invention relates to novel substituted pyrazolo[4,3-e]-diazepines of general formula: to pharmaceutical compositions containing them, to their use as medicinal products and to processes for preparing them. ... | 11/08/2005 |
| 6962923 | Pyrazole compositions Compounds of formulae (IA) and (IB): wherein R1, R2, R3, Ar1 and X are as defined above, are endothelin antagonists. The compounds are therefore useful in the treatment of a ... | 11/08/2005 |
| 6962931 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors CETP Inhibitors have improved solubility and bioavailability in a lipophilic vehicle comprising a digestible oil, a lipophilic solvent, or a surfactant. Preferred such compositions are self-emulsifying or self-microemulsifying, and comprise ... | 11/08/2005 |
| 6962993 | Pyrrolo[2,3-d]pyrimidine compounds A compound of the formula wherein R1, R2 and R3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3. ... | 11/08/2005 |
| 6960614 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystaline forms of oxygenated esters of 4-iodophenylamino benzhydr... | 11/01/2005 |
| 6958347 | Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists The present invention provides NPY-5 receptor antagonists having a Formula (I) Methods and pharmaceutical compositions useful for treating diseases, conditions and/or disorders modulated by the above NPY-5 receptor ant... | 10/25/2005 |
| 6958351 | NMDA NR2B antagonists for treatment The invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of NR2B subunit selective NMDA antagonists. The disorders that can be treating by the invention include heari... | 10/25/2005 |
| 6956113 | Bioluminescent assays and bacterial strains useful therein The present invention relates to novel assays for assessing the degree to which a cell is metabolically active. Also provided, are mutagenicity assays and, more specifically, methods for determining whether a given agent is genotoxic. Embodiments of the assays emplo... | 10/18/2005 |
| 6953810 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: ... | 10/11/2005 |
| 6951950 | Quaternary ammonium compounds The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis. ... | 10/04/2005 |
| 6951873 | Methods for treating age-related behavioral disorders in companion animals Methods for the treatment of age-related behavioral disorders in companion animals are disclosed. These comprise administering to a companion animal in need of such treatment a therapeutically effective amount of an acetylcholinesterase inhibitor. A preferred acetyl... | 10/04/2005 |
| 6951868 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease The invention provides compounds of Formula I: wherein Azabicyclo is any of: These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtu... | 10/04/2005 |
| 6949573 | Nicotinamide derivatives useful as PDE4 inhibitors The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful... | 09/27/2005 |
| 6949564 | NPY-5 antagonists The present invention provides NPY-5 receptor antagonists having a Formula (IA) Methods and pharmaceutical compositions useful for treating diseases, conditions and/or disorders modulated by the above NPY-5 receptor anta... | 09/27/2005 |
| 6946555 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor The invention provides a process for the preparation of a compound of the formula: or an acid addition or base salt thereof, wherein R is phenyl optionally substitute... | 09/20/2005 |
| 6943183 | 5-substituted tetralones as inhibitors of ras farnesyl transferase The present invention provides novel 5-substituted tetralones of Formulas I, II, III, and IV and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, ... | 09/13/2005 |
| 6939867 | β3 agonists and uses thereof Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with β-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and ... | 09/06/2005 |
| 6936600 | Sorbitol dehrydrogenase inhibitors This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R1, R2 and R3 are as defined in the specification. This invention is also directed to... | 08/30/2005 |
